Home / Market News / $KOD
benzinga Corporate Catalyst Impact 85/100 ● positive

Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One

Sep 28, 2026, 10:34 AM UTC · Primary ticker $KOD

Kodiak Sciences announced positive Phase 3 results for two key drug candidates, Zenkuda and Tabirafusp-ted, in wet age-related macular degeneration (wAMD), demonstrating non-inferiority to aflibercept. This significantly de-risks these assets and sets the stage for a multi-indication BLA filing for Zenkuda in late 2026, potentially transforming the company's future revenue streams.

Kodiak Sciences reported that its two investigational drugs, Zenkuda and Tabirafusp-ted, successfully met their primary endpoints in Phase 3 studies for wet age-related macular degeneration (wAMD). Zenkuda showed meaningful vision gains and sustained retinal drying, with a majority of patients on 6-month dosing, establishing a potential first-line benchmark. Tabirafusp-ted also met its vision and anatomical endpoints. This is a significant de-risking event for Kodiak, as positive Phase 3 data are crucial for regulatory approval and commercialization. The planned multi-indication BLA for Zenkuda in Q4 2026, encompassing five positive Phase 3 studies, suggests a robust pipeline and potential for substantial long-term revenue growth. For traders, this presents a strong buying opportunity for KOD in the short term due to increased confidence in its pipeline, while competitors like Regeneron (REGN) and Novartis (NVS) may face increased competitive pressure in the long term.

$KOD positive Successful Phase 3 results for key drug candidates
$REGN neutral Competitor with established wAMD treatment
$NVS neutral Competitor in ophthalmology market
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.